Original Research
Published on 09 Jun 2022
Ferroptosis-Related Long Noncoding RNAs as Prognostic Biomarkers for Ovarian Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.888699
- 3,174 views
- 12 citations
Type at least 3 characters
1,009 articles
Articles
Original Research
Published on 08 Jun 2022
Cucurbitacin B, Purified and Characterized From the Rhizome of Corallocarpus epigaeus Exhibits Anti-Melanoma Potential
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.903832
- 4,369 views
- 7 citations
Original Research
Published on 08 Jun 2022
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.889575
- 2,089 views
- 2 citations
Original Research
Published on 07 Jun 2022
Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.885656
- 4,030 views
- 11 citations
Original Research
Published on 07 Jun 2022
Ribonuclease A Family Member 2 Promotes the Malignant Progression of Glioma Through the PI3K/Akt Signaling Pathway
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.921083
- 1,946 views
- 6 citations
Original Research
Published on 07 Jun 2022
Associations of Prior Chronic Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Glucocorticoids With Cachexia Incidence and Survival
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.922418
- 2,008 views
- 5 citations
Original Research
Published on 03 Jun 2022
Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.893966
- 3,131 views
- 18 citations
Original Research
Published on 02 Jun 2022
FOXP4-AS1 Inhibits Papillary Thyroid Carcinoma Proliferation and Migration Through the AKT Signaling Pathway
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.900836
- 1,976 views
- 3 citations
Original Research
Published on 02 Jun 2022
CRIPTO Is a Marker of Chemotherapy-Induced Stem Cell Expansion in Non-Small Cell Lung Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.830873
- 2,473 views
- 4 citations
Review
Published on 01 Jun 2022
Investigating the Anticancer Potential of Salvicine as a Modulator of Topoisomerase II and ROS Signaling Cascade
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.899009
- 4,823 views
- 18 citations
Original Research
Published on 01 Jun 2022
CD3D Is an Independent Prognostic Factor and Correlates With Immune Infiltration in Gastric Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.913670
- 3,035 views
- 10 citations
Case Report
Published on 31 May 2022
Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.861271
- 2,755 views
- 5 citations
Original Research
Published on 31 May 2022
β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.896904
- 4,001 views
- 4 citations
Review
Published on 30 May 2022
The Interaction Between Epigenetic Changes, EMT, and Exosomes in Predicting Metastasis of Colorectal Cancers (CRC)
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.879848
- 5,258 views
- 15 citations
Mini Review
Published on 30 May 2022
Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.894214
- 4,820 views
Review
Published on 27 May 2022
Quality Assessment of Cancer Pain Clinical Practice Guidelines
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.890951
- 3,832 views
- 2 citations